WO1994013209A1 - Plaster for testing and method of testing - Google Patents
Plaster for testing and method of testing Download PDFInfo
- Publication number
- WO1994013209A1 WO1994013209A1 PCT/JP1993/001737 JP9301737W WO9413209A1 WO 1994013209 A1 WO1994013209 A1 WO 1994013209A1 JP 9301737 W JP9301737 W JP 9301737W WO 9413209 A1 WO9413209 A1 WO 9413209A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- patch
- parts
- adhesive
- inspection
- antigen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
- A61B10/0045—Devices for taking samples of body liquids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
- A61B10/0035—Vaccination diagnosis other than by injuring the skin, e.g. allergy test patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
- A61B10/0041—Detection of breast cancer
Definitions
- the present invention relates to a patch for testing which has various functions and is particularly preferably used for testing for breast cancer or atopic dermatitis, and a method for testing breast cancer or atopic dermatitis using the patch.
- breast cancer is known as one of the major cancers that is on the rise, but difficult to detect early.
- physician internal examination, palpation, mammography (X-ray), tumor markers [carcinoembryonic antigen (CEA), ⁇ -fetal protein (AFP), cancer antigen (CA15-3), various types Carbohydrate antigens] and ultrasonic waves are used, but the testing efficiency is not always high.
- tumor markers such as CEA, CA15-3 and AFP currently measure blood levels using radioimmunoassay (RIA) and enzyme immunoassay (EIA). Is the current situation.
- RIA radioimmunoassay
- EIA enzyme immunoassay
- the measurement of specific substances contained in serum, blood, biopsy samples, and the like is usually performed using physicochemical methods, biochemical methods, immunoassays, histopathological examinations, and the like. Therefore, the above biological sample cannot be measured at the medical site in general, and it is necessary to urgently require a few days for the measurement results to become clear, because the biological sample is requested to a facility with testing equipment or the test is entrusted to a special technician. In particular, there is a problem.
- arthropathic dermatitis disease has been increasing due to changes in living environment, a decrease in the ability of the living body to respond, and a decrease in immunity, and is becoming a major social problem.
- atopic diseases are diseases in Japan where the total number of patients or the number of latent patients is so high that it is said to be one or two in ten. The cause has not been fully elucidated, and its examination or treatment often relies on the physician's visual or empirical feeling.
- patches in the prior art include: (1) medical patches containing drugs such as salicylic acid-based anti-inflammatory analgesics and angina treatment drugs such as nitroglycerin; patch tests for irritation tests; and (2) allergic dermatitis.
- Patches for allergen detection to identify sensitizing substances such as (all systems that release drugs and other substances from the patches), (2) gauze, wound pads, or sanitary napkins
- pads for the purpose of hemostasis of secreted blood and exudate the purpose of capturing, and the purpose of antibacterial action such as wounds.
- the concept of applying directly to the breast including the dermal papilla and performing the test on the same patch was not known. .
- An object of the present invention is to solve these problems of the prior art, and to provide a short and simple non-invasive test capable of examining breast cancer or atopic dermatitis without limiting the examination place.
- the purpose of the present invention is to provide an adhesive patch and a method for testing the same.
- the location of the patch for testing is not limited at the place where the patch is applied or peeled off, the measurement person and the measurement location are not limited, and the measurement result is clearly shown in a short time, and doctors and nurses etc. To provide a rapid and simple breast cancer or atopic dermatitis test method which can be directly judged or tested at the medical site.
- the above object is achieved by preparing a patch for inspection having at least a liquid-permeable adsorption carrier.
- secretory immunoglobulin A secreted from a very small amount of skin contained in a liquid volume that is at least not visually recognizable as a liquid (naturally, a liquid volume that cannot be collected with a pipe etc.)
- the test for atopic dermatitis is achieved by performing adsorption and fixation using a patch for testing and immunologically measuring it.
- the patch for testing of the present invention comprises secretory substances secreted from the living body (a nipple secreted substance secreted from the nipple in the case of breast cancer test, and a trace amount secreted from the skin in the case of atopic dermatitis) Characterized in that it has at least an adsorbent carrier for adsorbing secretory immunoglobulin (secretory substance), and is particularly suitably used for breast cancer or atopic dermatitis testing. Furthermore, the test method of the present invention is characterized in that a target diagnostically useful secreted substance from a living body is measured using the test patch.
- the patch for inspection of the present invention will be described in detail.
- Examples of the support used in the present invention include non-stretch or non-stretch materials made of various resins such as paper, cloth, polyester resin, silicone resin, urethane resin, polyethylene resin, ethylene monoacetate copolymer, and soft polyvinyl chloride. Stretchable film, aluminum film, etc., alone or in combination thereof. Above all, a translucent or transparent support is particularly preferable in terms of accurate application position at the time of application, confirmation of an affected part, and simplicity of examination means at the time of examination.
- An adhesive is a substance that has adhesiveness or adhesiveness that does not adversely affect the application to the human body.
- a series of inspection means after the application of the adhesive for inspection is usually performed on the same adhesive.
- the substance must have the function of re-adhering to other fixtures.Adhesives must not interfere with the adsorption of the specific substance of interest on the adsorption carrier.
- the material used for the test is not translucent or that the combination with the support is a translucent or transparent material to confirm the application site of the patch for inspection. It is used as a mixture of various additives such as agents.
- the pressure-sensitive adhesive is spread over all, a part, or a part of the surface of the support. Specific examples of each component constituting the pressure-sensitive adhesive are described below. These are merely examples, and are not specified.
- the adhesive components include natural rubber, polyisobutylene rubber, polybutadiene rubber, silicone rubber, polyisoprene rubber, styrene-isopropylene styrene block copolymer (hereinafter abbreviated as SIS), and acrylic acid ester copolymer.
- Natural or synthetic resins such as polymer resins are exemplified.
- One or more of these pressure-sensitive adhesive components can be used.
- the compounding amount is in the range of 10 to 50% by weight, preferably 15 to 45% by weight, more preferably 20 to 40% by weight in the adhesive. Used in
- One or more rosins, hydrogenated rosins and their esters, polyterpene resins, petroleum resins, ester gums and the like can be used as a tackifier for the pressure-sensitive adhesive component for adjusting the tackiness.
- the compounding amount is 40% by weight or less, preferably 5 to 35% by weight, more preferably 15 to 30% by weight in the adhesive.
- one or more softeners such as liquid paraffin, polybutene, liquid polyisobutylene, and animal and vegetable oils can be used.
- the compounding amount is in the range of 5 to 60% by weight, preferably 10 to 50% by weight, more preferably 25 to 45% by weight in the adhesive.
- fillers such as titanium dioxide, synthetic aluminum gateate, zinc oxide, calcium carbonate, starch acrylate, and silicas can be used.
- the compounding amount is 5% by weight or less, preferably 0.1 to 4% by weight, more preferably 1 to 3% by weight in the pressure-sensitive adhesive.
- one or more absorbent polymers such as polyacrylates and starch-acrylic acid graft copolymers are blended in the adhesive for the purpose of water absorption and anti-fogging.
- the sample IM — 300, IM— 100, IM— 100,000 MPS, etc. manufactured by Sanyo Chemicals, trade name
- Aquakeep 4S, 4 SH manufactured by Iron and Steel Chemical, trade name
- Sumikagel SP— 52 0, N-100, etc. manufactured by Sumitomo Chemical Co., Ltd.
- Farasoap 800, 800F etc. manufactured by Arakawa Chemical Co., Ltd.
- an antioxidant such as sibutylhydroxytoluene is appropriately added to the adhesive in an amount of 3% by weight or less, if necessary.
- a drug such as an antihistamine or an antiallergic agent can be added to the adhesive in an appropriate amount, if necessary, for the purpose of preventing rash.
- the support having an adhesive spread on its surface (hereinafter referred to as an adhesive tape) has high and close contact with the skin, and the test patch is securely attached to the rot.
- the adsorptive carrier referred to in the present invention is, in terms of structure, directly bonded onto the above-mentioned pressure-sensitive adhesive or compounded as a powder in the pressure-sensitive adhesive, or indirectly bonded to a water-absorbing adsorption member via an adhesive. It is affixed to the adhesive in a functional manner, and is functionally a living body, It can efficiently adsorb secreted substances in the liquid secreted from the nipple and the like. Accordingly, the material of the adsorption carrier is substantially composed of one or more liquid-permeable materials. In addition, when one kind is mixed or adhered in or on the pressure-sensitive adhesive, it is necessary that this adsorption carrier has the following functions of absorbing and retaining water.
- the adsorption carrier is cellulose, carboxymethylcellulose, carboxymethylcellulose salt, hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, ethylcenorellose, canoleboxymethylethylsenorellose, hydroxypropylmethylcellulose, ethylhydroxyl.
- Cellulose derivatives such as cetyl cellulose, cellulose acetate, cellulose nitrate, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, or poly (2-hydroxy methacrylate), polyacrylic acid and polyvinyl alcohol-poly (acrylic acid) complex Or a fiber matrix such as polyurethane, polyester, polyethylene, polyvinyl chloride, polyvinylidene fluoride, nylon, etc.
- one or more kinds of paper for example, non-woven paper, filter paper), cloth (for example, cloth, cotton, silk, synthetic fiber) or porous ceramic such as silica, alumina, titania, zirconia, and ceria They are used in combination, but this does not apply if they have the above functions.
- the above-mentioned cellulose derivative is used as the adsorption carrier.
- this adsorbent is that it can be recognized as a small amount of liquid at the time of sweating or nipples with abnormal nipple secretion, etc. In some cases, it can be recognized as a relatively large amount of liquid, such as in urine or bleeding, and it is necessary to be able to respond to any of these as a patch for testing. preferable.
- the adsorption carrier it is necessary for the adsorption carrier to adsorb as much of the target secretory substance as possible even under the above-mentioned various conditions.
- a material having pores (voids or voids) or a matrix-like material hereinafter referred to as “material”.
- material a material having pores (voids or voids) or a matrix-like material (hereinafter referred to as “material”) is required.
- a pore With a pore). That is, it is preferable that the surface area of the adsorption carrier is substantially large. It is also necessary that the target secreted substance once adsorbed does not release during the test process. It is.
- the size of the pores of the adsorption carrier affects the ability to adsorb secretory substances, the permeability of secretory liquid, and the evaluation and evaluation of the test when the test patch is applied, but the pore size is 0.01 to 1%. It is 100 m, preferably 0.01 to 50 m, more preferably 0.01 to 30 / m. That is, if the pore size is very small, the adsorption carrier will be clogged, and if the pore size is very large, the amount of adsorption will be small or the determination will be difficult. This is one of the very important factors for the test patch. It is particularly desirable that the pore size of the cellulose derivative in the above-mentioned adsorption carrier is in the range of 0.01 to 50 m, preferably in the range of 0.01 to 30 m.
- the water-absorbing / adsorbing member referred to in the present invention is structurally compounded as a powder in the above-mentioned pressure-sensitive adhesive, directly adhered on the pressure-sensitive adhesive, or via an adhesive to the adsorption carrier. It is adhered and adhered directly onto the adhesive.
- extra (unnecessary for inspection) secretions or secretions after the target secretory substance is adsorbed by the adsorption carrier.
- this water-absorbing / adsorbing member is as a driving force of attraction when secretory liquid cannot be recognized and collected as a liquid at least with the naked eye, such as in a normal skin area, etc., and when it can be recognized as a small amount to a large amount of liquid. Since is used for the treatment of extra liquids and substances other than those for the purpose of measurement, it is preferable that the substance substantially has water absorbency and water retention and has substance adsorption.
- the water-absorbing / adsorbing member is substantially composed of a member having a water-absorbing / water-holding function and a Z or adsorption function, and includes a highly water-absorbing resin in addition to the liquid-permeable adsorption carrier.
- absorbent polymers such as alginate, cellulose, carboxymethylcellulose, carboxymethylcellulose salts, hydroxyshethylcellulose, hydroxypropylcellulose, methylcellulose, ethylcellulose, carboxymethylethylcellulose, hydroxypropylmethylcellulose
- absorbent polymers such as alginate, cellulose, carboxymethylcellulose, carboxymethylcellulose salts, hydroxyshethylcellulose, hydroxypropylcellulose, methylcellulose, ethylcellulose, carboxymethylethylcellulose, hydroxypropylmethylcellulose
- Cellulose derivatives such as ethylhydroxyl cellulose, cellulose acetate, cellulose nitrate, cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, or poly (2-hydroxyethyl methacrylate), polyacrylic acid and polyvinyl alcohol polyacrylic acid complex, etc.
- Porous gel, or fiber matrix or filter paper such as polyurethane, polyester, polyethylene, polyvinyl chloride, etc.
- the fabric is at least one selected, not limited as long as it has this function.
- the adsorption carrier and the water absorption / adsorption member are made of the same material, the amount, the pore size, the thickness, and the pretreatment can be appropriately combined.
- the adhesive is interposed between the two sheets when preparing an adhesive patch for inspection by using the adsorption carrier and the water-absorbing and adsorbing members as separate sheet materials, and they are completely bonded or partially bonded. It consists of
- the adhesive is not particularly limited as long as it is a substance having an adhesive property and does not affect the judgment.
- Polysaccharides such as tamarind seeds, gelatin, polyacrylic acid, polyacrylate, polyvinyl alcohol, polyethylene oxide, isobutylene-maleic anhydride copolymer, methoxyethylene-maleic anhydride copolymer, water-soluble epoxy
- examples thereof include natural or synthetic polymers such as resins, water-soluble acrylic resins, and water-soluble polyesters.
- This hydrophilic adhesive is preferable from the viewpoint of further absorbing the excess water absorbed by the adsorption carrier into the water-absorbing / adsorbing member, and also from the viewpoint of production.
- the release coating material is not particularly limited as long as it can protect the adsorption carrier layer.
- Preferred examples of the release coating material include release paper subjected to release treatment, cellophane, polyethylene, polypropylene, polyester, polyethylene terephthalate, and the like. High molecular Films and the like.
- the patch for inspection of the present invention examples include a rectangle, a round, an ellipse, a square, a triangle, and a fillet, but are not particularly limited as long as it is practical.
- the size and color are not particularly limited as long as they are practical.
- the patch for inspection of the present invention is desirably semi-transparent or transparent as an adhesive tape, and is provided with an identification mark on the support.
- the identification display means printing, engraving, or coloring upper, lower, left, and right signs or symbols on the support on the surface of the patch, for example, in order to identify the upper and lower sides of the left and right breast or skin.
- FIG. 1 The schematic cross-sectional view of the type (shape and configuration) of such a patch for inspection of the present invention is shown in FIG.
- 1 is a support
- 2 is an adhesive
- 3 is a water-absorbing / absorbing member
- 4 is an adhesive
- 5 is an adsorption carrier
- 6 is a release coating material.
- (a) and (b) have a two-layer structure
- (c) has a single-layer structure
- (d) has a blended structure.
- the two-layer structure means a structure in which the adsorption carrier 5 is provided on the pressure-sensitive adhesive 2, and the water-absorption adsorption member 3 is further provided thereon.
- This two-layer structure has an adhesive type in which an adhesive 4 is interposed between the adsorption carrier 5 and the water absorption / adsorption member 3 ((a) in the same figure), and no adhesive is interposed between the adsorption carrier 5 and the water absorption / adsorption member 3. It is roughly classified into a separation type ((b) in the same figure).
- the one-layer structure means a structure in which the adsorption carrier 5 is provided on the adhesive 2.
- the compounding structure refers to a structure in which the pressure-sensitive adhesive 2 contains a fine powdery adsorption carrier 5.
- the above-mentioned patch for breast cancer test is applied to the breast containing the nipple of a human body, and the nipple secretion substance is adsorbed and immobilized on an adsorption carrier, and the nipple secretion substance is measured. It is characterized by doing.
- the characteristics of the patch for breast cancer testing of the present invention are as follows: compared to contact methods other than sticking, the patch can be securely fixed to the affected area for a desired time, and can be detected at least without any amount of secretion fluid at an early stage. In the case of breast cancer (especially tumor-free), the primary site can be predicted.
- the patch for breast cancer test is applied to the nipple of the human body for a certain period of time so that the adsorbent carrier is the center. Then, the nipple secretion substance, which secretes a trace amount from the nipple, is Adsorb and solidify on the carrier.
- the nipple secretion substance here is a specific substance or protein secreted from the nipple as described above, or a constituent peptide thereof.
- Various tumor-associated antigens or tumor markers are selected for the immobilized nipple secretory substance.
- carcinoembryonic antigen Carcino embry onic antigen or less CEA
- melanoma cells melanoma marker
- PAL-Ml melanoma marker
- CE7 neuroblastoma
- AD 2 malignin, na-fetal protein (a-fet oprotein), psinogen, basic fetal protein (Basicfetoprotein), Teng cancer fetal antigen, fetal blealbumin, carbohydrate antigen (Ca) rb o hyd rate An tigen CA 19-9), Teng cancer associated antigen (CA 50), cancer antigen
- CA125 cancer antigen
- CA15-3 cancer antigen
- SCC squamous cell carcinoma
- Fr Sn seminoprotein
- PA prostate specific antigen
- TPA tissue polypeptide antigen
- I AP immune acidic protein
- immunosuppressive acidic protein prostate acidic protein
- PAP diuron specific enolase
- NSE diuron specific enolase
- blood enzymes (especially P ⁇ D, ALP) and amino acids (especially A1a, G1u), mucous substances, and other various hormones.
- enzymes especially P ⁇ D, ALP
- amino acids especially A1a, G1u
- mucous substances and other various hormones.
- these tumor-associated antigens or tumor markers can be quantitatively, semi-quantitatively, or qualitatively measured by an antigen-antibody reaction, a chemical reaction, or an enzymatic reaction using a specific antibody.
- CEA tumor-associated antigens or tumor markers
- CEA will be described as a representative example.
- CE A is a glycoprotein containing 668 amino acids and about 50% sugar. It is one of the clinically useful carcinoembryonic tumor-related antigens.
- Blood CEA is elevated in colorectal and other cancers, and is said to correspond to the degree of cancer progression. However, when the CEA migrates from the cancer tissue to the blood, the cancer has progressed considerably, and it has been mainly to confirm the postoperative course and the therapeutic effect of the drug.
- the present invention is to apply the above-mentioned patch for breast cancer examination to a nipple portion and measure CEA.
- an anti-CEA monoclonal antibody or a polyclonal antibody can be used in consideration of specificity and sensitivity.
- This antibody may be an antibody having high sensitivity and specificity to CEA.
- the patch for breast cancer examination which was applied to the affected area and peeled off after a certain period of time, was used for EIA, immunochromatography, immunoassay using latex-conjugated antibody, and immunoassay using gold colloid-conjugated antibody using this antibody. And fluorescence or luminescence immunoassay.
- the CEA secreted from the nipple can be detected as a spot (dot) or diffusely dense stained image at the portion corresponding to the primary site of cancer.
- Judgment is based on the density, size, and site of the stain, and the degree of disease progression, extent, and which mammary gland originates can be determined qualitatively, semi-quantitatively, and quantitatively by visual inspection, microscopy, densitography, etc. It can be carried out.
- the atopic dermatitis test method of the present invention comprises the steps of applying the above-mentioned patch for atopic dermatitis test to the skin, mucous membrane or diseased part of a human body, adsorbing secretions with an adsorption carrier and solidifying the secretions, It is characterized in that Ig A secretion is measured by an immunoassay.
- the patch for atopic dermatitis examination is applied to the skin, mucous membrane or diseased part of the human body for a certain period of time, for example, 1 minute to 30 hours. Then, the secretions are adsorbed and solid-phased on the adhesive carrier of the patch.
- the term “secretion” refers to the amount of liquid secreted along the sweat glands that cannot be visually recognized as a liquid or the amount of liquid that can be recognized, and includes sIgA contained therein.
- the sIgA secretion is selectively measured by an immunoassay. As a result, a strong dot-like stained image was observed at a site considered to be equivalent to the sweat glands of the skin.
- FIG. 1 is a schematic cross-sectional view specifically showing the shape and configuration of the patch for inspection of the present invention. -
- the final form is the adhesive patch for inspection
- the form consisting of the support and the adhesive is the adhesive tape
- the adsorbent carrier and the water-absorbent adhering member are the two-layer adsorbent carrier (adhesive type).
- An adhesive in which at least a powdery adsorbent carrier is blended is defined as an adsorbent carrier blend.
- the compounding values (parts) of each component of the pressure-sensitive adhesive in Table 1 are based on weight.
- Example 1 Test patch consisting of a two-layered adsorption carrier (adhesive type)
- Stretchable polyvinyl chloride film as a support, and as an adhesive
- a mixture of SIS, polyisobutylene, ester gum, and liquid paraffin (compounding ratio: 20 parts by weight: 10 parts by weight: 35 parts by weight: 35 parts by weight) was spread and 3 cm x
- Microporous polymer of cellulose ester (pore size: 0.6 ⁇ Millipore) for the water absorbing and adsorbing member and cellulose nitrate Z cellulose acetate (pore size: 0.45 / m Millipore) for the polyacrylic acid ester
- the two layers were bonded together to form a two-layer adsorption carrier. It was cut into a circle having a diameter of 1.5 cm, adhered to an adhesive tape via a water absorbing / adsorbing member, and the adsorption carrier side was covered with a polyethylene terephthalate film to prepare a patch for inspection.
- Example 2 Test patch consisting of a two-layer adsorbent (separable type)
- Stretchable flexible polyvinyl chloride film as a support, and as an adhesive
- Stretchable flexible polyvinyl chloride film as a support and SIS, polyisobutylene, ester gum, liquid paraffin, and starch acrylate as an adhesive (compounding ratio 22 parts by weight: 8 parts by weight: 33 parts by weight: 35 parts by weight: 2 parts by weight) The compound was spread to produce a circular adhesive tape having a diameter of 4 cm.
- a circular cellulose nitrate Z cellulose acetate (pore size: l / m manufactured by Millipore) having a diameter of 2 cm was adhered as an adsorption carrier on the adhesive tape, and covered with a polyethylene terephthalate film.
- stretchable flexible polyvinyl chloride film with a diameter of 2 cm, SIS, ester gum, liquid paraffin, aluminum gayate and powdered cellulose powder (compounding ratio 24 parts by weight: 35 parts by weight: 35 parts by weight) : 2 parts by weight: 4 parts by weight) was spread to prepare an adhesive tape having an adsorption ability. Cover the adhesive tape with polyethylene terephthalate film to produce a patch for inspection.
- Elastic soft port SIS 18 parts Microporous cell opening, Nitric acid cell D-cellose / Cellulose acetate-+ 'I 7I 4 "
- Liquid paraffin 57 parts (Milliboa) (Milli ⁇ : Ryosha)
- Hydrophilic poly (vinylidene fluoride),
- Fiber non-woven fabric Liquid paraffin 35 parts Bridge polymer Ilum
- Gin ester 20 parts Cellulose nitrate n-butyl acrylate /
- Acrylic acid starch graph (made by Sartorius)
- Liquid paraffin 53 parts (manufactured by Sartoriris)
- Stretchable polyethylene permeate 34 parts starch / acrylic graft polyethylene terephthalate
- Fluidized balla-in 37 parts (Millipo Ryosha)
- Acrylic acid graph of starch acid (Ato'Van Co., Ltd.)
- Example 4 Using the material shown in Example 4 as a support, a skin patch-colored soft polyvinyl chloride, translucent and transparent soft polyvinyl chloride was used to prepare a patch for inspection. A healthy man marked a mark on the inside of the upper arm of 10 males and used this as a target to attach the mark to the inside of the upper arm. The translucent or transparent material was more correctly applied to the target area. This proved that the translucent or transparent support could be applied more accurately.
- Hydrophilicity The adsorbent was immersed in water at 1 atm and 25 ° C for 1 minute to evaluate wettability.
- Adsorption amount Different serum albumin (BSA) was dropped onto the adsorption carrier, dried and immobilized. Immunostaining was performed using anti-BSA antibody to evaluate the amount of adsorbed carrier c
- test patch was applied to the inside of the upper arm of 10 healthy males for 24 hours, and the test patch was subjected to immunostaining using an anti-sIgA antibody after peeling.
- Irritation A patch for testing was applied to the inside of the upper arm of 10 healthy men for 24 hours. After peeling, the irritancy of the patch for inspection was evaluated.
- the relationship between the amount of protein adsorbed and the pore size of the patch for inspection is generally better when the pore size is smaller, but if the pore size is too small, clogging of BSA and liquid will occur, and if it is too large, the color of immunostaining will loosen. Visual judgment was weak. Therefore, a pore size of 0.01 to 100 m can be used, and a pore size in the range of 0.01 to 50 zm is preferred, and the result is obtained.
- the adsorption carrier of the patch for inspection has liquid permeability.
- Adhesives that do not affect the human body, do not interfere with the reaction system, and have re-adhesive properties are desirable.
- the water-absorbing and adsorbing member has a water-absorbing and water-retaining property and an adsorbing function.
- the adsorptive carrier has a high adsorptive function, has pores (increases the surface area), and is preferably liquid-permeable.
- the adhesive is preferably a water-permeable adhesive.
- Example 6 (adhesive tape: 3 cm x 4 cm oval, adsorbent: diameter 2 cm, circle) was applied to both nipples of two healthy adult married women (32, 40 years old). Peeled off after 5 minutes, 1 hour, 24 hours and 48 hours. The peeled patch was measured qualitatively and semi-quantitatively in Experimental Example 2. Table 4 shows the results.
- nipple secretion-derived CEA could not be detected in two healthy adult women.
- Example 1 The test patch obtained in Example 1 was applied to both nipples of patient A (49 years old) whose right breast was diagnosed with breast cancer for 24 hours. After 24 hours, the specimen peeled off and a patch for inspection in which CEA was immobilized as a calibration curve were blocked with milk protein, and then reacted with an anti-CEA antibody. Next, a peroxidase-labeled anti-mouse Ig was reacted, and the color was developed with diaminobenzidine and hydrogen peroxide. Color development was stopped with 2 M sulfuric acid. The stained specimens were observed qualitatively, semi-quantitatively and quantitatively. Table 5 shows the results. Table 5 Staining results of breast cancer patients
- the patch for inspection attached to the right nipple developed a diffuse dark and brown color.
- the patch for breast cancer test applied on the left side did not develop any color.
- test patch prepared in Example 31 was applied to the left and right nipples for 24 hours to 9 healthy subjects and 8 patients. After peeling, staining was performed by the method of Experimental Example 2. The results are expressed in terms of staining intensity and are shown in Table 6.
- An optimal anti-human CEA monoclonal antibody was allowed to react with 2 Onm of gold colloid 1 Oml for 1 hour. After blocking with 1% bovine serum albumin, antibody-sensitized gold colloid particles were obtained by centrifugation at 800 g for 1 hour. A buffer was used to prepare a sensitized colloid solution of 3.0 at OD 530 nm.
- Example 23 Using this colloid solution, it was prepared in Example 23 and evaluated using the patient performed in Experimental Example 6. Table 8 shows the results.
- test patch adheresive tape: 3 cm x 4 cm oval, adsorbent carrier; 1.5 cm diameter circle
- Example 1 The test patch of Example 1 was applied to the left nipple of a breast cancer patient with nipple discharge (40 years old, left: breast cancer) and the left of a breast cancer patient without nipple discharge (45 years old, left; breast cancer). The nipples were stuck on their own for 24 hours. Furthermore, the same patient was contacted with a liquid-impermeable sheet (Mammotech) on which an anti-CEA antibody was immobilized in the same manner for 24 hours.
- a liquid-impermeable sheet Mommotech
- the evaluation was performed by detecting the CEA using the application or contact time and immunostaining. The results are shown in Table 10.
- liquid-impermeable sheet did not allow 24 hours of contact, and the contact position of both breast cancer patients shifted within 1 or 2 minutes.
- Example 1 The patch for test described in Example 1 was applied to the forehead, chest, inner arm, and palms of five healthy adult men and women, and peeled after 10 minutes, 6 hours, and 24 hours. Exfoliated samples were qualitatively measured by enzyme-linked immunoassay. In addition, various types of sticking areas were used depending on the site. Table 11 shows the results. Table 11 1 Method of application and amount of secreted sIgA
- the adhering area of the adsorbent carrier can be sufficiently measured even in a range of several mm 2 to 10 cm 2 , and it was found that the adhering carrier is not limited to the area and the applying time.
- An anti-human sIgA monoclonal antibody (mouse IgGl) was allowed to react for 20 hours with the test patch sample of Example 2 attached to a healthy adult male. Next, after blocking with bovine serum albumin, a peroxidase-labeled anti-mouse IgG antibody ( ⁇ Sagi) was reacted. For the color development, a diaminobenzidine solution of 0.2 SmgZm 1 and a hydrogen peroxide solution of 0.0125% were mixed in a ratio of 1: 1 (volZvol) and added. Three minutes later, a 2 mol sulfuric acid solution was added to stop the reaction.
- Example 1 Health test patch samples of Example 1 was applied to adult male four, and the Kohi preparative s I g A monoclonal antibody (murine I gG l) and allowed to react for 2 hours. Then cow blood After blocking with purified albumin, a peroxidase-labeled anti-mouse IgG antibody (Egret) was reacted. For the color development, 1.5 mg / ml of ortho-perylenediamine solution and 1% of hydrogen peroxide solution were mixed in 1: 1 (volZvol) and added. Three minutes later, 1% sulfuric acid solution was added to stop the reaction, and the absorption at 490 nm was quantitatively measured by a spectrophotometer. Table 12 shows the standard sIgA calibration curve, and Table 13 shows the skin sIgA secretion of healthy adult males.
- Example 1 of the present invention (adhesive tape; 3 cm in diameter, 1.5 cm square in an adsorption carrier) was applied to the chest for 5 minutes. The sample obtained by attaching to the sample was directly permeated into this latex-labeled anti-sIgA monoclonal antibody solution. The results are shown in Table 14.
- test patch of Example 2 of the present invention was applied to the inside of the forearm for 24 hours to 19 healthy persons and 19 patients with Aatby's dermatitis. After peeling, staining was performed by the method of Experimental Example 12. The results are shown in Table 16.
- the present invention as described above has the following effects.
- the patch for testing of the present invention is non-invasive, its location is limited in a short time and easily. Can be attached without using. In addition, it is an extremely safe patch with little side effects such as irritation or rash when applied to the skin for a long time.
- test patch of the invention conventionally, can be trapped tumor Ma one car of trace of secreting the could not be taken nipple as the liquid. Since the trapped marker can be measured quantitatively or qualitatively and simply and easily, multi-item measurement is possible.
- CEA cancer-derived neurotrophic ANCA
- measurement of CEA or tumor markers is useful for breast cancer testing, and in particular, enables mass screening and mass screening for non-mass-free and early breast cancer.
- the location of the patch allows prediction of the primary tumor location in breast cancer. As a result, the efficiency of breast cancer testing is expected to increase.
- the patch for testing of the present invention can specifically and simply measure quantitatively or qualitatively the amount of sIgA secreted from the skin which could not be collected as a conventional solution.
- determination can be made visually within a few minutes after the patch is peeled off, so that it can be measured quickly and easily at medical sites.
- the measurement of sIgA using the patch for atopic dermatitis examination of the present invention is useful for the examination of atopic dermatitis.
- the patch and the method for testing breast cancer or atopic dermatitis of the present invention are suitably used for testing breast cancer or atopic dermatitis.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002151144A CA2151144A1 (en) | 1992-12-07 | 1993-11-29 | Diagnostic patch and method for diagnosis using the same |
JP06513985A JP3129738B2 (ja) | 1992-12-07 | 1993-11-29 | 検査用貼付剤および検査方法 |
AU55752/94A AU5575294A (en) | 1992-12-07 | 1993-11-29 | Plaster for testing and method of testing |
EP94901015A EP0737442A1 (en) | 1992-12-07 | 1993-11-29 | Plaster for testing and method of testing |
US08/454,113 US6063029A (en) | 1992-12-07 | 1993-11-29 | Diagnostic patch and method for diagnosis using the same |
KR1019950702297A KR0163647B1 (en) | 1992-12-07 | 1995-06-07 | Diagnostic patch |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP35117192 | 1992-12-07 | ||
JP4/351171 | 1992-12-07 | ||
JP4/353901 | 1992-12-16 | ||
JP4353901A JPH0632733A (ja) | 1992-05-18 | 1992-12-16 | アトピー性皮膚炎検査用貼付剤およびアトピー性皮膚炎検査方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994013209A1 true WO1994013209A1 (en) | 1994-06-23 |
Family
ID=26579335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1993/001737 WO1994013209A1 (en) | 1992-12-07 | 1993-11-29 | Plaster for testing and method of testing |
Country Status (8)
Country | Link |
---|---|
US (1) | US6063029A (ja) |
EP (1) | EP0737442A1 (ja) |
JP (1) | JP3129738B2 (ja) |
KR (1) | KR0163647B1 (ja) |
CN (1) | CN1099482A (ja) |
AU (1) | AU5575294A (ja) |
CA (1) | CA2151144A1 (ja) |
WO (1) | WO1994013209A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002257831A (ja) * | 2001-02-28 | 2002-09-11 | Kaihatsu Komonshitsu:Kk | パッチテスト用シート |
JP2002372527A (ja) * | 2001-06-13 | 2002-12-26 | Fujirebio Inc | 経血又は膣分泌物採取器具、キット及び方法 |
WO2005083428A1 (ja) * | 2004-02-26 | 2005-09-09 | Pixen, Inc. | 診断用センサ |
JP2013504759A (ja) * | 2009-09-18 | 2013-02-07 | ザ プロクター アンド ギャンブル カンパニー | 痒みの客観的測定値として皮膚からヒスタミンを測定するための非侵襲的方法 |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6148233A (en) * | 1997-03-07 | 2000-11-14 | Cardiac Science, Inc. | Defibrillation system having segmented electrodes |
US20010008614A1 (en) * | 1998-11-16 | 2001-07-19 | Jack L. Aronowitz | Sample collection system and method of use thereof |
US6471660B1 (en) | 1999-01-21 | 2002-10-29 | Chandice Covington | Method and apparatus for measuring factors in mammary fluids |
US6251083B1 (en) * | 1999-09-07 | 2001-06-26 | Amira Medical | Interstitial fluid methods and devices for determination of an analyte in the body |
KR100433614B1 (ko) * | 2000-06-16 | 2004-05-31 | 주식회사 태평양 | 친수성 또는 염의 형태로 된 약물을 함유하는 경피흡수제제 |
US6443892B1 (en) * | 2000-09-28 | 2002-09-03 | The United States Of America As Represented By The Secretary Of The Navy | Sweat collecting device and methods for use and detection of tampering |
US6585646B2 (en) * | 2000-11-29 | 2003-07-01 | Hermetic Diagnostics, Inc. | Screening test and procedure using skin patches |
US20020117169A1 (en) * | 2001-02-27 | 2002-08-29 | Kurz Daniel R. | Cover and applicator for a portion of a mammalian body |
US6866994B2 (en) * | 2001-05-30 | 2005-03-15 | Neomatrix, Llc | Noninvasive intraductal fluid diagnostic screen |
US20030073951A1 (en) * | 2001-05-30 | 2003-04-17 | Morton Kevin B. | Disposable patient interface for intraductal fluid aspiration system |
US20030069482A1 (en) * | 2001-10-09 | 2003-04-10 | Workman Jerome James | Sampling article for determining quantitative and qualitative drug transfer to skin |
EP1485027A1 (en) * | 2002-03-19 | 2004-12-15 | Cytyc Corporation | Method and apparatus for analyzing mammary gland fluid |
WO2004034059A1 (en) * | 2002-10-11 | 2004-04-22 | Sentina Biotechnology Incorporated | Methods for detection of breast cancer |
US7190986B1 (en) * | 2002-10-18 | 2007-03-13 | Nellcor Puritan Bennett Inc. | Non-adhesive oximeter sensor for sensitive skin |
DE102004039570B4 (de) * | 2004-08-14 | 2007-03-01 | Lts Lohmann Therapie-Systeme Ag | Überwachungssystem zum Sammeln und zur transdermalen Weiterdiffusion von Umweltkontaminantien enthaltender Luft und Verfahren hierzu |
WO2008141318A1 (en) * | 2007-05-14 | 2008-11-20 | Dr. Susan Love Research Foundation | Device for determining risk of developing breast cancer and method thereof |
US20100069726A1 (en) * | 2008-06-04 | 2010-03-18 | Seventh Sense Biosystems, Inc. | Compositions and methods for rapid one-step diagnosis |
CN102405015B (zh) | 2009-03-02 | 2017-01-18 | 第七感生物系统有限公司 | 用于分析可提取介质的装置和方法 |
WO2012018486A2 (en) | 2010-07-26 | 2012-02-09 | Seventh Sense Biosystems, Inc. | Rapid delivery and/or receiving of fluids |
US8778387B2 (en) | 2009-09-02 | 2014-07-15 | Hyprotek, Inc. | Antimicrobial medical dressings and protecting wounds and catheter sites |
JP5406646B2 (ja) * | 2009-09-16 | 2014-02-05 | シスメックス株式会社 | 組織液収集方法に用いる組織液収集キット及び組織液収集シート |
FR2955024B1 (fr) * | 2010-01-14 | 2012-02-10 | Commissariat Energie Atomique | Dispositif de mise en contact transitoire d'au moins une unite de capture de cibles biologiques avec un fluide les contenant, et procede de recuperation des cibles capturees |
BR112012018170B8 (pt) | 2010-01-22 | 2021-05-25 | Hyprotek Inc | agente antimicrobiano para redução, inibição ou tratamento do crescimento microbiano, infecções microbianas, doenças inflamatórias, doenças ou condições virais resultantes de ou associadas aos mesmos |
WO2011094573A1 (en) | 2010-01-28 | 2011-08-04 | Seventh Sense Biosystems, Inc. | Monitoring or feedback systems and methods |
WO2011163347A2 (en) | 2010-06-23 | 2011-12-29 | Seventh Sense Biosystems, Inc. | Sampling devices and methods involving relatively little pain |
US20120016308A1 (en) | 2010-07-16 | 2012-01-19 | Seventh Sense Biosystems, Inc. | Low-pressure packaging for fluid devices |
WO2012021801A2 (en) | 2010-08-13 | 2012-02-16 | Seventh Sense Biosystems, Inc. | Systems and techniques for monitoring subjects |
EP2992827B1 (en) | 2010-11-09 | 2017-04-19 | Seventh Sense Biosystems, Inc. | Systems and interfaces for blood sampling |
EP3106092A3 (en) | 2011-04-29 | 2017-03-08 | Seventh Sense Biosystems, Inc. | Systems and methods for collecting fluid from a subject |
ES2597081T3 (es) | 2011-04-29 | 2017-01-13 | Seventh Sense Biosystems, Inc. | Entrega y/o recepción de fluidos |
US20130158468A1 (en) | 2011-12-19 | 2013-06-20 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving material with respect to a subject surface |
WO2012149126A1 (en) | 2011-04-29 | 2012-11-01 | Seventh Sense Biosystems, Inc. | Plasma or serum production and removal of fluids under reduced pressure |
US10617472B2 (en) | 2012-02-06 | 2020-04-14 | Hyprotek, Inc. | Adhesive patch with antimicrobial composition |
WO2013179141A1 (en) * | 2012-05-31 | 2013-12-05 | University Of Oslo | Sampling medium |
JP6130130B2 (ja) * | 2012-12-04 | 2017-05-17 | シスメックス株式会社 | 体液収集具 |
WO2017146503A1 (ko) * | 2016-02-23 | 2017-08-31 | 노을 주식회사 | 패치를 이용하는 ctc 진단 방법 및 장치 |
WO2017146502A1 (ko) * | 2016-02-23 | 2017-08-31 | 노을 주식회사 | 중합 효소 연쇄 반응 패치, 이를 이용하는 진단 방법 및 장치 |
US10371610B2 (en) | 2016-02-23 | 2019-08-06 | Noul Co., Ltd. | Contact-type patch, staining method using the same, and manufacturing method thereof |
WO2017146504A1 (ko) * | 2016-02-23 | 2017-08-31 | 노을 주식회사 | 항체 제공 키트, 항체 저장 패치, 이를 이용하는 면역 진단 방법 및 장치 |
KR20170099737A (ko) * | 2016-02-23 | 2017-09-01 | 노을 주식회사 | 접촉식 염색 패치 및 이를 이용하는 염색 방법 |
JP2017184844A (ja) * | 2016-04-01 | 2017-10-12 | セイコーエプソン株式会社 | 検出装置、第1検出システム、及び第2検出システム |
WO2019068047A1 (en) * | 2017-09-29 | 2019-04-04 | W.L. Gore & Associates, Inc. | FLUID HANDLING DETECTORS |
WO2019112889A1 (en) * | 2017-12-05 | 2019-06-13 | Abbott Diabetes Care Inc. | Medical devices having a dynamic surface profile and methods for production and use thereof |
WO2022004685A1 (ja) * | 2020-07-02 | 2022-01-06 | パナソニックIpマネジメント株式会社 | 機能性部材とこれを備えた化学物質センサー |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6453165A (en) * | 1987-08-24 | 1989-03-01 | Shiseido Co Ltd | Preparation of cutaneous cell sample |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8404895L (sv) * | 1984-10-01 | 1986-03-17 | Torkel Ingemar Fischer | Medel for en overkenslighetstest |
US4788971A (en) * | 1987-07-13 | 1988-12-06 | Hill Top Research, Inc. | Patch system for use on the skin |
US5203327A (en) * | 1988-09-08 | 1993-04-20 | Sudor Partners | Method and apparatus for determination of chemical species in body fluid |
JPH02176466A (ja) * | 1988-12-27 | 1990-07-09 | Mochida Pharmaceut Co Ltd | 液性試料中の特定物質の測定方法および測定器具 |
-
1993
- 1993-11-29 AU AU55752/94A patent/AU5575294A/en not_active Abandoned
- 1993-11-29 US US08/454,113 patent/US6063029A/en not_active Expired - Fee Related
- 1993-11-29 WO PCT/JP1993/001737 patent/WO1994013209A1/ja not_active Application Discontinuation
- 1993-11-29 CA CA002151144A patent/CA2151144A1/en not_active Abandoned
- 1993-11-29 JP JP06513985A patent/JP3129738B2/ja not_active Expired - Fee Related
- 1993-11-29 EP EP94901015A patent/EP0737442A1/en not_active Withdrawn
- 1993-12-07 CN CN93120139A patent/CN1099482A/zh active Pending
-
1995
- 1995-06-07 KR KR1019950702297A patent/KR0163647B1/ko not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6453165A (en) * | 1987-08-24 | 1989-03-01 | Shiseido Co Ltd | Preparation of cutaneous cell sample |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002257831A (ja) * | 2001-02-28 | 2002-09-11 | Kaihatsu Komonshitsu:Kk | パッチテスト用シート |
JP4704583B2 (ja) * | 2001-02-28 | 2011-06-15 | 有限会社開発顧問室 | パッチテスト用シート |
JP2002372527A (ja) * | 2001-06-13 | 2002-12-26 | Fujirebio Inc | 経血又は膣分泌物採取器具、キット及び方法 |
JP4534388B2 (ja) * | 2001-06-13 | 2010-09-01 | 富士レビオ株式会社 | 経血又は膣分泌物採取器具、キット及び方法 |
WO2005083428A1 (ja) * | 2004-02-26 | 2005-09-09 | Pixen, Inc. | 診断用センサ |
KR101026440B1 (ko) * | 2004-02-26 | 2011-04-07 | 가부시키가이샤 심스 | 진단용 센서 |
JP2013504759A (ja) * | 2009-09-18 | 2013-02-07 | ザ プロクター アンド ギャンブル カンパニー | 痒みの客観的測定値として皮膚からヒスタミンを測定するための非侵襲的方法 |
Also Published As
Publication number | Publication date |
---|---|
JP3129738B2 (ja) | 2001-01-31 |
KR0163647B1 (en) | 1998-12-15 |
AU5575294A (en) | 1994-07-04 |
EP0737442A1 (en) | 1996-10-16 |
CN1099482A (zh) | 1995-03-01 |
KR950703893A (ko) | 1995-11-17 |
CA2151144A1 (en) | 1994-06-23 |
EP0737442A4 (en) | 1996-06-17 |
US6063029A (en) | 2000-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3129738B2 (ja) | 検査用貼付剤および検査方法 | |
JP3299330B2 (ja) | 簡易測定装置および方法 | |
JP2002542843A (ja) | 検出装置を備える使い捨て用品およびその他の用品 | |
US10605809B2 (en) | Rapid test for the qualitative and/or quantitative analysis of antibodies against human papilloma viruses (HPV) present in body fluid, and device for carrying out the rapid test | |
US20100256464A1 (en) | Device for determining risk of developing breast cancer and method thereof | |
EP2463656A1 (en) | An immunochromatography device for the diagnosis of diseases in a sample | |
JP2021532332A (ja) | ベータコア断片hCGをマーカーとして含む新規な妊娠診断装置 | |
JP3359391B2 (ja) | 腫瘍検査用貼付剤及びそれを用いる検査方法 | |
CN212808318U (zh) | 检测胎儿纤维连接蛋白和人胰岛素样生长因子结合蛋白-1的试纸条及包含其的装置 | |
CN111643274A (zh) | 一种用于胎膜早破精准检测的护垫 | |
JPH11166929A (ja) | 検査用貼付剤及び検査方法 | |
JP2019513234A (ja) | 生体試料を収集するためのおむつ | |
JPH0632733A (ja) | アトピー性皮膚炎検査用貼付剤およびアトピー性皮膚炎検査方法 | |
WO2024085240A1 (ja) | おりもの用テストストリップを有する吸収性物品、及び、吸収性物品で用いるためのおりもの用テストストリップ | |
WO2023037391A1 (en) | Strip adhered absorbent sanitary article for detecting analyte levels and its production thereof | |
CN219289926U (zh) | 一种验孕和性病检测护垫 | |
US11234680B2 (en) | Diaper for collecting biological samples | |
CN116819070B (zh) | 用于体液中目标物检测的试纸条、检测装置及检测方法 | |
US20140303516A1 (en) | Urine collection device | |
DE102004032253A1 (de) | Vorrichtung zur intravaginalen Probenahme von Menstrualblut mit integriertem immunologischen Schnelltest zur Erkennung einer Endometriose | |
TW467736B (en) | Feminine sanitary disposable article having a blood detection means as sensor | |
TW201329450A (zh) | 檢測女性癌症之套組 | |
JP2004361206A (ja) | メンブレンアッセイ法 | |
Test | Bowel Health Test | |
TWM469484U (zh) | 檢測女性癌症之裝置 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BG BR CA CZ FI HU JP KR NO NZ PL RU UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1994901015 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2151144 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08454113 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1994901015 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994901015 Country of ref document: EP |